CN114452295A - Use of lacto-N-tetraose for preventing intestinal leakage - Google Patents
Use of lacto-N-tetraose for preventing intestinal leakage Download PDFInfo
- Publication number
- CN114452295A CN114452295A CN202111447439.5A CN202111447439A CN114452295A CN 114452295 A CN114452295 A CN 114452295A CN 202111447439 A CN202111447439 A CN 202111447439A CN 114452295 A CN114452295 A CN 114452295A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- powder
- tetraose
- lacto
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 35
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 title claims abstract description 18
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 title claims abstract description 18
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 210000005027 intestinal barrier Anatomy 0.000 claims abstract description 12
- 230000007358 intestinal barrier function Effects 0.000 claims abstract description 11
- 230000003870 intestinal permeability Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 28
- 235000013350 formula milk Nutrition 0.000 claims description 24
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- 235000020610 powder formula Nutrition 0.000 claims description 6
- 210000001723 extracellular space Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 11
- 230000035699 permeability Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 6
- 238000004977 Hueckel calculation Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004692 intercellular junction Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides the use of lacto-N-tetraose for the prevention of intestinal leakage. Specifically, the invention provides application of lacto-N-tetraose in preparing food or medicine for preventing intestinal leakage, wherein the prevention of intestinal leakage comprises improvement of intercellular intestinal permeability and intestinal barrier. Wherein the prevention of intestinal leakage comprises improving intercellular intestinal permeability and intestinal barrier.
Description
Technical Field
The invention relates to a new application of lactose-N-tetrasaccharide, in particular to an application of lactose-N-tetrasaccharide in preparing food or medicine for preventing intestinal leakage.
Background
Intestinal leakage (leaky gut), refers to the phenomenon in which increased intestinal permeability causes harmful substances in the intestine, such as bacteria and toxins, to pass through the intestinal mucosa into other tissues, organs and blood circulation in the human body. Gut permeability is associated with gut barrier function, and normal gut permeability depends on the integrity of the gut mucosal barrier. The intestinal mucosal barrier is a complex multi-layered system including physical, chemical, biological and immunological barriers. The interaction of these barriers allows the intestinal tract to maintain a permeability balance, preventing the loss of water and electrolytes and the entry of antigens and microorganisms into the body, while allowing molecular exchange between the body and the environment and the absorption of nutrients in the food.
The intestinal physical barrier, which is the first line of defense against the external environment, occupies a central position in the intestinal barrier structure and is composed of intestinal epithelial cells and intercellular junctions. Intestinal cell permeability is largely divided into transepithelial or transcellular permeability and paracellular permeability. Cell bypass permeability is dependent on transport through interstitial spaces between cells. The intercellular junction includes tight junction, adhesion junction, desmosomes, etc., and most importantly, the tight junction is located at the apical end of the intestinal epithelial cell outer membrane and has a long and narrow band-like structure to block the intercellular space, thereby preventing macromolecular substances such as bacteria and toxins, etc. in the intestinal lumen from entering the blood circulation through the intercellular space. The intercellular tight junction structure has high dynamic stability, and its permeability determines the barrier function of the whole intestinal epithelial cell, and is regulated by intracellular and extracellular signals, and can be affected by diet, diseases, stress, etc.
The intestinal chemical barrier is mainly composed of the mucus layer, which can alter the sites of intestinal microorganisms, preventing them from coming into direct contact with the host intestinal tissue cells. In addition, some substances produced in the intestinal tract, such as bile salts, mucopolysaccharides, lysozyme and glycoproteins, can also play a role in chemical barriers.
The intestinal biological barrier is a micro-ecosystem with dynamic stability formed by intestinal symbiotic bacteria and a host, the intestinal symbiotic bacteria are attached to a mucous membrane layer on the surface of the intestinal tract of the host to form a microbial barrier formed by bacteria, and the intestinal biological barrier inhibits the colonization and the propagation of pathogenic bacteria through mechanisms such as competitive adhesion.
In the intestinal immunity barrier, intestinal tract-related lymphoid tissues play a role in juggling, wherein lymphocytes, macrophages and the like play a role in resisting pathogen invasion, and in intestinal tract immunity effector molecules, secretory immunoglobulin A (sIgA) plays a key role, is produced in an intestinal tract lamina propria and is secreted into an intestinal cavity after being processed by intestinal tract epithelial cells, can block adhesion of antigens such as bacteria, toxins and viruses on mucous membranes, and plays a role in clearing the antigens.
Intestinal leakage due to dysfunction of the intestinal barrier is a major potential cause of many health problems, including irritable bowel syndrome, headache, weight gain, hashimoto's thyroiditis, anxiety, depression, autoimmune diseases and allergies, among others. In particular, microbial toxins produced by the metabolism of the intestinal flora or other toxins entering with food enter the blood circulation through the intestinal wall with increased permeability ("intestinal leakage"), and cause various autoimmune symptoms by stimulating the autoimmune system or poisoning internal organs, thereby causing various diseases.
Compared with the infants fed by breast milk, the infants not fed by breast milk have poor intestinal development and are easy to have intestinal leakage.
Therefore, there is a need for a solution that can prevent the occurrence of intestinal leakage to promote intestinal health.
Disclosure of Invention
The invention finds that some lactose-N-tetrasaccharides have the function of preventing intestinal leakage so as to promote intestinal health.
In particular, the invention provides the use of lacto-N-tetraose (LNT) in the manufacture of a food or pharmaceutical product for the prevention of the occurrence of intestinal leakage. Wherein the prevention of intestinal leakage comprises improving intercellular intestinal permeability and intestinal barrier.
lacto-N-tetraose, a hexasaccharide structure formed by lactose and tetraose, is a representative substance of oligosaccharides having a core sugar chain as a basic structure and containing no fucosyl group or sialyl group. Most of lactose-N-tetraose commodities in the prior art are prepared by a microbial fermentation method, and have the same structure as lactose-N-tetraose oligosaccharide found in human milk.
According to a particular embodiment of the invention, in the use of lacto-N-tetraose according to the invention, said prevention of intestinal leakage comprises reducing intercellular spaces.
According to a particular embodiment of the invention, the lactose-N-tetraose of the invention is used in food products comprising one or more of nutritional supplements, non-infant milk powder, liquid milk, infant formula powder (infant formula), and supplementary food. Wherein the non-infant milk powder can be milk powder for children or milk powder for adults (including the middle-aged and the elderly).
In some embodiments of the invention, the lactose-N-tetraose of the invention is used in a food product which is an infant formula.
According to some embodiments of the invention, the lactose-N-tetraose of the invention is used in food products in an amount of: the application amount of the non-infant milk powder or infant formula powder is 14.2-2273.0mg/100g powder, or 0.02-3.0g/L calculated by converted milk.
According to some embodiments of the invention, the lactose-N-tetraose of the invention is used in food products in an amount of: the application amount of the non-infant milk powder or infant formula powder is 70.9-1515.3mg/100g powder, or 0.1-2.0g/L calculated by converted milk.
According to some embodiments of the invention, the lactose-N-tetraose of the invention is used in food products in an amount of: the application amount of the non-infant milk powder or infant formula powder is 70.9-757.7mg/100g powder, or 0.1-1.0g/L calculated by converted milk.
In another aspect, the present invention provides a food or pharmaceutical product comprising lacto-N-tetraose in an amount effective to prevent the occurrence of intestinal leakage.
According to a specific embodiment of the present invention, the food or pharmaceutical product of the present invention may further comprise ingredients conventionally used in the art. For example, for pharmaceutical products, suitable excipients may be included, which may be excipients, diluents, fillers and/or absorption enhancers, and the like. The food or pharmaceutical product may take on different forms depending on the needs of the recipient. Such as powders, lozenges, granules, microcapsules and/or liquid formulations, and the like.
In conclusion, the lactose-N-tetrasaccharide can be used for preventing or improving intestinal leakage or intestinal barrier damage, can be added into food, is favorable for improving intercellular intestinal permeability and intestinal barrier, improves intercellular gaps, and is particularly favorable for maintaining the intestinal health of infants.
Drawings
Figure 1 shows the effect of the LNT of the invention on the molecular transport profile of FD 4.
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description taken in conjunction with the accompanying specific embodiments, and the technical solutions of the present invention are described, it being understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention. In the examples, the respective starting reagent materials are commercially available, all the breast milk oligosaccharide (HMO) starting material is from the supplier Jennewein, and the experimental procedures without particular indications of conditions are conventional procedures and conditions well known in the art, or as recommended by the manufacturer of the apparatus.
Example 1
In the embodiment, the influence of different types of HMOs and compositions thereof on the epithelial function of the small intestine under normal conditions is examined, and the improvement of intercellular intestinal permeability and intestinal barrier (improvement of cell bypass permeability) is realized through indexes such as intestinal barrier and FD4 (fluorescein isothiocyanate dextran; FITC labeled dextran) molecular transport condition and the like.
Normal (non-invasive) condition
Caco-2 cells were cultured in DMEM medium in a transwell system for 21 days to simulate the small intestine epithelial cell layer. The test HMO or HMO composition (final concentration 0.1mg/mL in the culture system) was added and cultured for 24 hours, and then FD4 molecule (final surface concentration 250ug/mL) was added and the culture was continued. FD4 molecular transport was measured as three biological replicates at 24 hours of continued culture. A DMEM medium control was also set without any HMO or HMO composition tested.
Data analysis
The permeability data of FD4 for molecular transport was statistically analyzed using two-tailed paired T-test. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.
Results of the experiment
The results are shown in FIG. 1. The LNT provided by the invention has the advantages that the FD4 molecular transport (P <0.05) is remarkably reduced, the LNT provided by the invention is shown to improve the intercellular intestinal permeability (the intercellular intestinal permeability is reduced), and the intestinal barrier effect is improved, and the analysis reason is mainly to reduce the intercellular gap and improve the intercellular tightness, so that the tightness of the paracellular transport pathway is increased, and the intestinal leakage can be effectively reduced.
Example 2 infant formula with added breast milk oligosaccharides
The embodiment provides infant formula milk powder with the age of 0-6 months, wherein the formula milk powder contains 11.1g/100g of total protein, 28.3g/100g of fat, 52.9g/100g of carbohydrate and 0.4g/100g of breast milk oligosaccharide LNT.
Claims (10)
1. Use of lacto-N-tetraose in the manufacture of a food or pharmaceutical product for the prevention of the occurrence of intestinal leakage, wherein the prevention of intestinal leakage comprises improving intercellular intestinal permeability and intestinal barrier.
2. The use according to claim 1, wherein the food or pharmaceutical product is for reducing intercellular spaces.
3. Use according to claim 1, wherein the food or pharmaceutical product is for formula-fed infants and young children.
4. The use of claim 1, wherein the food product comprises one or more of a nutritional supplement, liquid milk, non-infant milk powder, infant formula powder, or a complementary food.
5. Use according to claim 4, wherein the food product is an infant formula.
6. Use according to claim 4, wherein the lacto-N-tetraose is applied in the food product in an amount of: the application amount of the non-infant milk powder or infant formula powder is 14.2-2273.0mg/100g powder, or 0.02-3.0g/L calculated by converted milk.
7. Use according to claim 6, wherein the lacto-N-tetraose is applied in the food product in an amount of: the application amount of the non-infant milk powder or infant formula powder is 70.9-1515.3mg/100g powder, or 0.1-2.0g/L calculated by converted milk.
8. Use according to claim 6, wherein the lacto-N-tetraose is applied in the food product in an amount of: the application amount of the non-infant milk powder or infant formula powder is 70.9-757.7mg/100g powder, or 0.1-1.0g/L calculated by converted milk.
9. The use according to claim 3, wherein the medicament further comprises pharmaceutically acceptable excipients comprising excipients, diluents, fillers and/or absorption enhancers.
10. A food product comprising lacto-N-tetraose in an amount effective to prevent the development of intestinal leakage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447439.5A CN114452295A (en) | 2021-11-30 | 2021-11-30 | Use of lacto-N-tetraose for preventing intestinal leakage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447439.5A CN114452295A (en) | 2021-11-30 | 2021-11-30 | Use of lacto-N-tetraose for preventing intestinal leakage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114452295A true CN114452295A (en) | 2022-05-10 |
Family
ID=81406711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111447439.5A Pending CN114452295A (en) | 2021-11-30 | 2021-11-30 | Use of lacto-N-tetraose for preventing intestinal leakage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114452295A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| CN113163833A (en) * | 2018-12-21 | 2021-07-23 | 雀巢产品有限公司 | Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function |
| CN113194961A (en) * | 2018-12-21 | 2021-07-30 | 格礼卡姆股份公司 | Compositions and methods for promoting intestinal barrier healing |
| CN113194746A (en) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier |
-
2021
- 2021-11-30 CN CN202111447439.5A patent/CN114452295A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113163833A (en) * | 2018-12-21 | 2021-07-23 | 雀巢产品有限公司 | Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function |
| CN113194961A (en) * | 2018-12-21 | 2021-07-30 | 格礼卡姆股份公司 | Compositions and methods for promoting intestinal barrier healing |
| CN113194746A (en) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063079A (en) | Glycan therapeutics and related methods thereof | |
| Coppa et al. | Preliminary study of breastfeeding and bacterial adhesion to uroepithelial cells | |
| Perlmutter et al. | d-Lactic acidosis in children: An unusualmetabolic complication of small bowel resection | |
| EP2604689B1 (en) | Anti-obesity agent and anti-obesity food | |
| US20030040492A1 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN114128767B (en) | Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides | |
| Rosado et al. | Lactose maldigestion and milk intolerance: a study in rural and urban Mexico using physiological doses of milk | |
| EP2668851B1 (en) | Liver function-improving agent | |
| TW202128190A (en) | Compositions comprising 2’-fucosyllactose to prevent asthma | |
| Brandelli | Probiotics: advanced food and health applications | |
| CN114451453B (en) | Breast milk oligosaccharide composition for preventing intestinal leakage and application thereof | |
| CN114452295A (en) | Use of lacto-N-tetraose for preventing intestinal leakage | |
| CN114145354A (en) | Formula milk powder containing breast milk oligosaccharide for preventing intestinal leakage and preparation method and application thereof | |
| CN104824511A (en) | Prebiotics composition | |
| US20220218772A1 (en) | Mushroom blend for increasing butyrate production in the gut biome | |
| JP4330088B2 (en) | Tight junction permeation inhibitor | |
| RU2325166C1 (en) | Pharmaceutical formulation of antibiotics and lactulose applied for prevention of enteral disbiosis caused by antibiotic therapy | |
| CN116262125B (en) | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof | |
| CN109275714A (en) | A kind of relieving alcoholism and protecting liver Yoghourt and preparation method thereof | |
| WO2024005043A1 (en) | Nutritional composition for preventing bronchitis | |
| JP3693377B2 (en) | Peptide mixture having infection-protecting action in vivo and composition containing this peptide mixture | |
| CN114271340A (en) | Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof | |
| US20240148778A1 (en) | Glycoside inhibitors of yeast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |